Does Medicare Cover Zepbound?

💊🛡️

GLP-1 Bridge · Part D OSA Coverage · BMI Criteria · Prior Authorization · $50 Copay

The answer changed in mid-2026 — but it’s not as simple as yes or no. There are now three separate pathways, each with different rules, different qualifying conditions, and different out-of-pocket costs. Which one applies to you depends on why your doctor is prescribing Zepbound.

$50/mo Flat copay under the Medicare GLP-1 Bridge program — down from ~$1,087 list price per month

July 1 Date the GLP-1 Bridge launched — weight-loss coverage through December 31, 2027

BMI 27+ Minimum qualifying BMI for Bridge — with a documented qualifying condition alongside it

⚕️ Medical and Coverage Disclaimer: This guide explains Medicare coverage rules for Zepbound based on publicly available CMS policy and FDA indications. It is not medical advice and does not replace a conversation with your doctor or pharmacist. Coverage eligibility, formulary placement, and prior authorization requirements vary by plan and change frequently. Always confirm your specific plan’s rules before filling a prescription.

📋 Key Takeaways — The Answers People Search for First

Zepbound coverage under Medicare is now a moving landscape. These are the most important facts, answered briefly — each one opens for the full explanation.

1 Does Medicare cover Zepbound for weight loss? As of July 1, 2026, yes — but only through a temporary program called the Medicare GLP-1 Bridge, not through your regular Part D plan. You must have Part D coverage, meet BMI criteria, get prior authorization, and be prescribed the KwikPen formulation specifically. ▼

For the first time in Medicare’s history, weight-loss drugs are now reachable through a Medicare program — but through a pilot, not a permanent benefit. The GLP-1 Bridge is a CMS demonstration project running from July 1, 2026, through December 31, 2027. It covers the Zepbound KwikPen (not single-dose pens or vials) for eligible Part D enrollees who meet specific BMI thresholds and have their prescriber submit prior authorization. The copay is a flat $50 per month regardless of dose. Importantly, this program operates entirely outside the normal Part D benefit — your Part D plan doesn’t need to add Zepbound to its formulary for you to access it, because CMS handles approvals and payments through its own central processor. If you don’t meet the Bridge criteria or you have a qualifying medical condition like sleep apnea or diabetes, a different coverage pathway may apply.

2 Why didn’t Medicare cover Zepbound for weight loss before now? Federal law — specifically Section 1862 of the Social Security Act — explicitly prohibits Medicare Part D from covering drugs prescribed for weight loss. This law has been in place since Part D was created in 2003. The GLP-1 Bridge works around it as a separate CMS demonstration, not by changing the statute. ▼

The exclusion is not a coverage decision that CMS made on its own — it’s written into federal law. Section 1862(a)(1)(A) of the Social Security Act lists drugs used for weight loss among the services Medicare cannot cover. Congress enacted this when creating Part D in 2003, and it remains in force. The GLP-1 Bridge sidesteps this by operating as a CMS demonstration project authorized under separate research authority rather than as a Part D benefit. This is why your regular Part D plan doesn’t handle the Zepbound weight-loss claim — it legally cannot. Instead, CMS built a separate administrative system with its own prior authorization process, its own claims processor, and its own direct pharmacy payment system. The long-term status of weight-loss drug coverage after December 2027 depends on Congressional action — it is not guaranteed to continue.

3 Does Medicare cover Zepbound for sleep apnea? Yes — Medicare Part D can cover Zepbound when prescribed specifically for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This is a separate, currently available pathway through your regular Part D plan — not through the GLP-1 Bridge. Prior authorization and a sleep study are typically required. ▼

In December 2024, the FDA approved Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity — a completely separate indication from its weight-loss approval. Because this prescription is for sleep apnea, not weight loss, Medicare’s weight-loss exclusion doesn’t apply. Your regular Part D plan can cover it, subject to formulary placement and prior authorization. The key documents your doctor will typically need to submit: a diagnosis of moderate-to-severe OSA confirmed by a sleep study, documentation of obesity, and evidence that Zepbound is medically appropriate for this indication. Not every Part D plan has added Zepbound for OSA to its formulary — some have, some haven’t, and some are still deciding. If your plan doesn’t list it, you can request a formulary exception based on medical necessity. The OSA coverage pathway is also important for people who have both sleep apnea and a desire to lose weight — the CMS rules specify that anyone eligible for Part D coverage of a GLP-1 through an existing indication (like OSA) must use that Part D pathway rather than the GLP-1 Bridge.

4 What is the BMI requirement for the GLP-1 Bridge? BMI 35 or higher qualifies automatically. BMI 30–34.9 qualifies if you also have heart failure (with preserved ejection fraction), uncontrolled hypertension on two medications, or chronic kidney disease. BMI 27–29.9 qualifies only with pre-diabetes, prior heart attack or stroke, or peripheral artery disease. The BMI used is from when you first started GLP-1 therapy, not your current weight. ▼

CMS structured the Bridge eligibility around three BMI tiers, each with its own rules. The highest tier (BMI 35+) has no additional condition requirement — if you’re at or above that threshold when you began GLP-1 therapy, you qualify. The middle tier (BMI 30–34.9) requires a documented comorbidity: heart failure with preserved ejection fraction, uncontrolled high blood pressure being managed with two or more medications, or chronic kidney disease Stage 3a or higher. The lowest tier (BMI 27–29.9) requires one of a narrower set of conditions: pre-diabetes as defined by American Diabetes Association guidelines, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease. The critical nuance that helps people who’ve lost weight: eligibility is assessed at the time you first started GLP-1 therapy, not your current BMI. If you began Zepbound in 2024 with a BMI of 37 and your BMI is now 31, your prescriber attests to the 37 — your current lower BMI doesn’t disqualify you. This is explicit CMS policy and can prevent denials for people who have already made progress.

5 Which formulation of Zepbound does Medicare cover — and which does it not? The Medicare GLP-1 Bridge covers only the Zepbound KwikPen — a multi-dose device containing four doses per pen, used once weekly. Single-dose vials and single-dose pens are explicitly excluded from the Bridge. The OSA pathway through regular Part D covers whichever formulations your plan’s formulary includes. ▼

This distinction matters at the pharmacy counter. The Zepbound KwikPen is a reusable-style auto-injector that holds four doses, meaning one pen lasts approximately 28 days. It requires separate pen needles, which are not included and must be obtained separately — your doctor can prescribe needles alongside the Zepbound prescription. Lilly’s single-use prefilled pens and the single-dose vials that became popular through compounding-alternative discussions are not eligible under the Bridge program. If your current Zepbound prescription specifies single-dose pens or vials, ask your doctor to update it to the KwikPen formulation before July 1 if you want to use the Bridge. For the OSA pathway through regular Part D, your plan’s formulary determines which formulations are covered — this is plan-specific and worth confirming with your pharmacist before assuming coverage.

6 Can I use the Lilly savings card or manufacturer coupons with Medicare? No. Federal law prohibits manufacturer savings cards, copay coupons, and patient assistance programs from being used by Medicare and Medicaid beneficiaries. This is not a Lilly policy — it’s a federal anti-kickback rule. The GLP-1 Bridge’s $50 copay is the alternative discount path for Medicare patients. ▼

Lilly’s $25/month savings card for Zepbound explicitly excludes “patients who are enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government program.” This exclusion exists because of anti-kickback statutes — using manufacturer coupons alongside government insurance is considered an illegal inducement under federal law. This is one of the most commonly misunderstood cost-saving options for Medicare patients, and pharmacists regularly have to explain the restriction to people who bring in coupons they found online. The only legitimate Medicare pathways to reduced Zepbound cost are the GLP-1 Bridge ($50/month for eligible weight-loss prescriptions), Part D coverage under an OSA or diabetes indication at whatever your plan’s cost-sharing structure yields, or paying entirely in cash outside your Medicare coverage — for example, through LillyDirect’s self-pay vial program, which starts around $299–$449 per month and bypasses insurance entirely. Extra Low Income Subsidy (LIS/Extra Help) may also reduce costs for qualifying low-income beneficiaries if their plan covers Zepbound.

7 I already take Zepbound and pay out of pocket — can I switch to Medicare coverage? Possibly yes, through the GLP-1 Bridge, if you have Part D coverage and meet the BMI criteria at the time you started therapy. Have your doctor submit a prior authorization to CMS. If you already have Part D, your existing plan continues, and the Bridge operates separately from it. ▼

Patients who have been paying cash for Zepbound — whether through LillyDirect, a compounding pharmacy, or full retail price — can transition to the GLP-1 Bridge coverage if they meet the eligibility criteria. The key is that the BMI threshold is evaluated at initiation of GLP-1 therapy, not today. So if you started Zepbound a year ago at BMI 36 and your doctor can document that, you likely qualify under the BMI 35+ tier even if your weight has dropped since. The enrollment process requires no separate application from you — your prescriber submits a prior authorization to CMS’s central processor, and once approved, you simply fill the next prescription at a participating pharmacy and pay the $50 copay. For patients who don’t currently have Medicare Part D coverage, this is a prerequisite — the Bridge is only available to Part D enrollees. If you’re on Original Medicare without Part D, you’d need to enroll in a Part D plan first, keeping in mind Medicare’s enrollment periods.

8 What happens to Zepbound coverage after the GLP-1 Bridge ends in December 2027? Unknown. The Bridge was designed to “bridge” to a longer-term CMS program called the BALANCE Model, which was supposed to launch in January 2027 — but as of mid-2026, the BALANCE Model did not happen. What comes after December 2027 depends on Congressional action, which has not been committed to. Do not assume permanent coverage. ▼

The Medicare GLP-1 Bridge was explicitly described as a temporary demonstration intended to bridge the gap while a more permanent program — the BALANCE Model — was developed. The BALANCE Model was scheduled to begin in January 2027, but it did not materialize as planned. CMS extended the Bridge through December 2027 specifically to allow additional time to collect data and evaluate options. What happens after that depends on whether Congress passes legislation to permanently repeal or modify the weight-loss drug exclusion in the Social Security Act, or whether CMS creates another demonstration. Neither outcome is guaranteed. Patients who begin Zepbound under the Bridge should be aware that coverage may end in December 2027, with no certainty of what follows. The OSA pathway through regular Part D is not time-limited in the same way — it can continue as long as the FDA indication exists and plans include it in their formularies.

🔀 The Three Medicare Pathways for Zepbound — Which One Is Yours?

Medicare’s relationship with Zepbound now involves three distinct routes, each governed by different rules. The path that applies to you is determined by why Zepbound is being prescribed — not by how much you want it or what your BMI is.

← Swipe left to see full table →

Pathway	Indication	Coverage Via	Status	Copay Est.
GLP-1 Bridge	Weight loss / obesity only	CMS central processor — outside Part D	Live July 1, 2026	$50/month flat
Part D — OSA	Obstructive sleep apnea + obesity	Your regular Part D or MA-PD plan	Available now	Plan-specific (~$50+)
Part D — Diabetes	Type 2 diabetes	Part D covers Mounjaro (same molecule as Zepbound) for diabetes	Available now	Plan-specific
No Coverage	Weight loss only (before July 1, 2026)	Not applicable	Ended June 30	Full retail ~$1,087/mo

⚠️ The Rule That Surprises Most People

If you have a qualifying condition that makes Zepbound coverable through regular Part D — such as moderate-to-severe sleep apnea — you cannot use the GLP-1 Bridge. CMS rules require that anyone with a Part D-coverable indication must go through their regular Part D plan for that indication. The Bridge is exclusively for people whose only qualifying reason for Zepbound is weight management, and who do not have a condition like OSA or diabetes that opens a standard Part D route. This means the Bridge and the OSA pathway are mutually exclusive — you go through one or the other, not both.

🌉 The Medicare GLP-1 Bridge — How It Works and Who Qualifies

The Bridge is a CMS pilot program that began July 1, 2026. It is not a permanent Medicare benefit — it runs through December 31, 2027. Within those dates, eligible Part D enrollees can access the Zepbound KwikPen for weight management at a flat $50 monthly copay.

🌉 GLP-1 Bridge — Eligibility Requirements

✅

Tier 1 · Simplest Qualification · No Additional Condition Needed BMI 35 or Higher at Therapy Initiation

✅ Qualifies automatically — no comorbidity required

If your BMI was 35 or higher when you first started any GLP-1 medication, you qualify for the Bridge without needing to document any additional health condition alongside it. Your prescriber attests to this BMI on the prior authorization form. Critically: if you’ve lost weight since starting Zepbound and your BMI has dropped below 35 by July 2026, this does not disqualify you — CMS evaluates eligibility based on BMI at therapy initiation, not current weight. A patient who began Zepbound in 2024 at BMI 38 and is now at BMI 31 after successful treatment still qualifies under this tier, because the 38 is what’s attested to on the authorization request.

📏 BMI 35+ at start of GLP-1 therapy ✅ No additional diagnosis required 📋 Prior authorization required from prescriber

📋

Tier 2 · Needs a Qualifying Comorbidity · Specific Conditions Listed BMI 30–34.9 with a Cardiovascular or Kidney Condition

✅ Qualifies — with documented comorbidity

At this BMI range, you need one of three documented conditions in your medical record. Heart failure with preserved ejection fraction (HFpEF) is one. Uncontrolled high blood pressure being actively managed with two or more different blood pressure medications is another. Chronic kidney disease at Stage 3a or higher is the third. Your prescriber must document which condition applies. All three are fairly common among Medicare beneficiaries — if you’re in this BMI range and have high blood pressure or kidney concerns, it’s worth asking your doctor whether you meet one of these criteria.

📏 BMI 30–34.9 at therapy start ❤️ Heart failure (HFpEF) qualifies 💊 Hypertension on 2+ medications qualifies 🫘 CKD Stage 3a or higher qualifies

📋

Tier 3 · Narrower Conditions · Prediabetes or Vascular History BMI 27–29.9 with Pre-Diabetes or Vascular Disease History

⚠️ Qualifies only with a specific documented history

The lowest BMI tier has a narrower set of qualifying conditions. Pre-diabetes as defined by American Diabetes Association criteria (typically HbA1c 5.7–6.4%) is one path. A documented history of prior heart attack (myocardial infarction) is another. A previous stroke qualifies. Symptomatic peripheral artery disease — poor circulation in the legs that causes symptoms like cramping when walking — is the fourth option. Note that this tier requires specific medical history, not just current risk factors. “High blood pressure” alone does not qualify at this BMI level — it must be active hypertension managed with two medications (that qualifies under Tier 2). If you fall in this BMI range, review your medical history with your doctor carefully to see whether any of these conditions appear in your records.

📏 BMI 27–29.9 at therapy start 🩸 Pre-diabetes (HbA1c 5.7–6.4%) qualifies ❤️ Prior heart attack or stroke qualifies 🦵 Peripheral artery disease qualifies

🚫 Who Is NOT Eligible for the GLP-1 Bridge

Anyone with type 2 diabetes — your GLP-1 should go through Part D as Mounjaro (same tirzepatide molecule, diabetes indication)
Anyone with moderate-to-severe obstructive sleep apnea — you must use the Part D OSA pathway instead
Anyone without Medicare Part D coverage — the Bridge requires active Part D enrollment
TriCare, employer group waiver plan subscribers — the Bridge is for standard Part D and MA-PD plans only
Anyone whose Zepbound prescription is for single-dose vials or pens — only the KwikPen formulation is covered

🔑 How the Bridge Works at the Pharmacy

The GLP-1 Bridge operates entirely outside your regular Part D plan. Your doctor submits a prior authorization request directly to CMS’s central processor — not to your Part D plan. Once approved (usually within 24–72 hours after the pharmacy sends the PA form to your doctor), the next fill is processed as a Bridge claim. You go to the pharmacy, present your Medicare card, and pay the $50 copay. After the first fill is approved, subsequent refills do not require a new prior authorization unless you switch to a different covered GLP-1. The $50 copay applies regardless of which dose level you’re on — whether you’re on the lowest 2.5 mg dose or the highest 15 mg dose, the copay is the same $50.

😴 Zepbound for Sleep Apnea — The Part D Pathway That Already Exists

This pathway is separate from the GLP-1 Bridge and does not have an expiration date. If you have moderate-to-severe obstructive sleep apnea and obesity, your regular Part D plan may cover Zepbound today — if it’s on the formulary.

😴 What Medicare Requires for OSA Coverage

Diagnosis of moderate-to-severe obstructive sleep apnea: Must be confirmed by a formal sleep study (polysomnography in a lab) or a validated home sleep apnea test. Your doctor’s clinical impression alone is not sufficient — the sleep study result needs to be in your medical record.
Obesity: Body mass index typically at or above 30, or documentation of overweight with obesity-related manifestations that make you a candidate for this treatment.
Prescription specifically for OSA: The prescription must cite the OSA indication — not weight loss. The same drug with a weight-loss indication code on the prescription goes through different (and previously non-existent) channels.
Prior authorization: Almost universally required by plans that cover Zepbound for OSA. Your doctor submits documentation including the sleep study results.

💡 Sleep Apnea Is Severely Underdiagnosed — This Matters

Studies estimate that 80–90% of people with moderate-to-severe obstructive sleep apnea have never been formally diagnosed. If you snore loudly, wake frequently during the night, feel unrefreshed after sleep, or your bed partner has noticed you stop breathing during sleep — these are classic symptoms. A sleep study, which can now be done at home with a small device, can confirm or rule out the diagnosis. For Medicare patients with obesity who have been denied Zepbound under weight-loss rules, an unrecognized sleep apnea diagnosis could open a completely different — and currently available — coverage pathway. Talk to your doctor about whether a sleep study makes sense for your situation.

📋 What to Do If Your Plan Doesn’t Cover Zepbound for OSA

Not every Part D plan has added Zepbound to its formulary for the OSA indication. If yours hasn’t, you have two options. First, request a formulary exception — your doctor submits a written request explaining the medical necessity of Zepbound specifically for your OSA given your clinical history. Plans must respond to exceptions within 72 hours (or 24 hours for urgent requests). Second, if denied, you can appeal through Medicare’s standard appeals process: redetermination by your plan, then Independent Review Entity (IRE) reconsideration, then an Administrative Law Judge hearing if needed. Denial letters are worth appealing — the OSA indication is FDA-approved and the medical rationale is well-documented in clinical literature.

💉 If You Have Type 2 Diabetes — Mounjaro Is the Path, Not Zepbound

Zepbound and Mounjaro contain the same active ingredient — tirzepatide. The FDA approves them for different conditions under different brand names. Medicare covers Mounjaro for type 2 diabetes through regular Part D — but it does this as Mounjaro, not as Zepbound.

💉 Same Molecule, Different Brand, Different Coverage

Tirzepatide was first approved by the FDA as Mounjaro for type 2 diabetes management in May 2022. It was later approved as Zepbound for chronic weight management in November 2023 and for obstructive sleep apnea in December 2024. Medicare Part D can cover Mounjaro for diabetes because diabetes treatment is not subject to the weight-loss exclusion. If your doctor prescribes Zepbound (the brand name used for weight management and OSA) instead of Mounjaro for your diabetes, your Part D plan may reject the claim — because the drug is being prescribed under its weight-management brand identity, not its diabetes identity. Ask your prescriber to specify Mounjaro when the goal is diabetes management to avoid confusion at the pharmacy counter.

🩺 The Coverage Cliff — A Real Scenario Many Seniors Face

Consider a Medicare patient with BMI 38, pre-diabetes (A1C of 6.2%), and mild sleep apnea. Their A1C hasn’t crossed the diabetes threshold (6.5%), and their sleep apnea is too mild to meet the moderate-to-severe threshold for the OSA coverage pathway. Before July 2026, this patient had essentially no Medicare coverage for Zepbound — only the GLP-1 Bridge now helps them. But another patient with essentially the same health profile whose A1C crosses 6.5% qualifies for Part D coverage of Mounjaro immediately. The same drug, the same clinical picture, separated by 0.3% on a blood test. This is the “coverage cliff” that defines Zepbound access and underscores why the Bridge program matters for people who fall just short of diabetes but clearly have metabolic risk.

💰 What Zepbound Actually Costs With Medicare — Every Scenario

The gap between Zepbound’s retail price and what Medicare patients actually pay is enormous — but only if you qualify for one of the coverage pathways. Here is what the numbers look like across every situation.

← Swipe left to see full table →

Situation	Coverage Path	Monthly Cost	Annual Max
Eligible for GLP-1 Bridge	CMS Bridge program — KwikPen only	$50/month flat	$600/year
OSA + obesity, Part D covers Zepbound	Regular Part D formulary	Varies by plan tier	Capped at $2,100 OOP
Type 2 diabetes, Part D covers Mounjaro	Part D — Mounjaro (same molecule)	Varies by plan tier	Capped at $2,100 OOP
Low Income Subsidy (Extra Help)	Bridge or Part D with LIS	$0–$11 copay range	Minimal
No coverage — cash pay (LillyDirect vials)	Self-pay outside Medicare	$299–$449/month	$3,588–$5,388/year
No coverage — full retail list price	No assistance	~$1,087/month	~$13,044/year

💰 The Low Income Subsidy — Often Missed

Medicare’s Extra Help program (also called Low Income Subsidy or LIS) provides significant cost reductions for beneficiaries with limited income and resources. In 2026, full LIS beneficiaries pay very low copays on covered Part D drugs and have no coverage gap or deductible. If you’re on Medicaid, receive Medicare Savings Program assistance, or have limited income and assets, you may qualify for Extra Help automatically or through a Social Security application. Under the GLP-1 Bridge, LIS beneficiaries may qualify for a reduced copay — reportedly as low as $0–$11 for some LIS categories. Call 1-800-Medicare or visit ssa.gov/medicare/part-d to check whether Extra Help applies to your situation.

📋 Prior Authorization — What It Is and What Your Doctor Needs to Submit

Prior authorization is the step that slows most people down. It doesn’t happen automatically when your doctor writes a prescription — it’s a separate review process. Understanding what’s required prevents delays.

📋 For the GLP-1 Bridge — How Prior Authorization Works

Your prescriber submits the prior authorization directly to CMS’s central processor — not to your Part D plan. When you take a Bridge-eligible Zepbound prescription to the pharmacy, the pharmacist sends the claim to the Bridge processor. If the Bridge processor cannot confirm your eligibility automatically, it sends a prior authorization request form directly to your prescriber, typically within 24–72 hours. Your doctor completes the form attesting to your BMI at therapy initiation and relevant qualifying conditions, then returns it. Once the first fill is approved, subsequent refills don’t require re-authorization unless you switch to a different covered GLP-1 medication. Your prescriber does not need to be enrolled in Medicare specifically to prescribe Bridge-covered drugs or to submit prior authorization.

📋 For the OSA Pathway — What Documentation Your Doctor Needs

Sleep study results: Polysomnography (in-lab sleep study) or validated home sleep apnea test showing moderate-to-severe OSA — typically an AHI (apnea-hypopnea index) of 15 or higher
BMI documentation: Current documented BMI in the medical record
Obesity diagnosis: Physician documentation that the OSA is related to obesity
Prior treatment history: Some plans require evidence that CPAP was tried and failed or was contraindicated — called step therapy. This is plan-specific, not a universal requirement.
Letter of medical necessity: Your doctor’s written explanation of why Zepbound specifically, rather than another treatment, is appropriate for your OSA given your clinical situation

⏱️ Timeframes Medicare Plans Must Follow

Medicare has legally mandated response times for prior authorization requests. For standard requests, your plan must respond within 72 hours. For urgent or expedited requests — when a delay would seriously jeopardize your health — plans must respond within 24 hours. If your plan misses these deadlines, that is grounds for an expedited appeal. Ask your doctor to mark the request as expedited if there is a clinical reason for urgency. Once a prior authorization is approved, plans cannot retroactively deny previously approved and filled prescriptions without giving you advance notice and an opportunity to appeal.

⚖️ If Your Zepbound Claim Is Denied — What to Do Next

A denial is not the end. Medicare has a structured appeals process with multiple levels, and coverage denials for Zepbound — particularly for OSA — are frequently reversed on appeal when the documentation is complete.

🔴 Read Your Denial Letter First — The Reason Matters

Every denial must come with a written explanation of why coverage was denied. Read it carefully before reacting — the reason determines the correct appeal strategy. Common denial reasons for Zepbound include: “Drug not on formulary” (requires a formulary exception, not an appeal), “Weight loss drugs are excluded” (true for standard Part D, but the Bridge is the workaround — confirm the claim was routed to the Bridge processor), “Step therapy required” (CPAP may need to be documented as tried or contraindicated for OSA cases), and “Insufficient documentation” (missing sleep study results or BMI documentation). Each denial reason has a different specific fix, and targeting the wrong response wastes time.

📋 The Medicare Appeals Ladder

Step 1 — Redetermination: File within 60 days of the denial. Your plan reviews the case again, typically with a fresh set of eyes. Must respond within 7 days for coverage decisions (60 days for payment decisions). Include any additional documentation your doctor can provide.
Step 2 — Reconsideration by Independent Review Entity (IRE): If denied again, file within 60 days. An independent organization — not your plan — reviews the case. Must respond within 7 days. This step has historically produced reversals in a significant percentage of GLP-1 cases with strong clinical documentation.
Step 3 — Administrative Law Judge (ALJ) Hearing: If the amount in dispute meets the threshold ($180 in 2026), you can request a hearing before an ALJ within 60 days. This is the step where strong legal and clinical arguments carry the most weight.
Steps 4 and 5 — Medicare Appeals Council and Federal Court: Higher levels of appeal available if lower levels fail, with additional threshold requirements.

💡 Getting Help With an Appeal

You don’t have to navigate appeals alone. Your State Health Insurance Assistance Program (SHIP) provides free, unbiased counseling to Medicare beneficiaries — including help understanding denials and filing appeals. Find your local SHIP at shiphelp.org or by calling 1-800-Medicare. Your doctor’s office can also file appeal documentation on your behalf — the provider’s clinical statement supporting medical necessity is often the single most persuasive document in a GLP-1 appeal.

☎️ 1-800-Medicare (633-4227) 🔗 SHIP Help — shiphelp.org 🛡️ medicare.gov

🙋 Your Situation — What to Do Based on Where You Are Right Now

📏 My BMI is 35+ and I have Medicare Part D — what do I do?

You likely qualify for the GLP-1 Bridge under Tier 1, the simplest category. Talk to your doctor about Zepbound for weight management. Ask them to submit a prior authorization to CMS’s Bridge processor when you’re ready to start. Make sure the prescription specifies the KwikPen formulation, not single-dose vials or pens. You’ll also need a prescription for pen needles separately since they’re not included with the KwikPen. Budget $50 per month plus the pen needle cost. If you already take Zepbound and pay out of pocket, your prescriber can retroactively attest to your BMI at therapy initiation if it was 35+ at that time.

😴 I snore, feel tired, and my BMI is over 30 — should I get a sleep study?

Discuss this with your doctor — the symptoms you describe are consistent with obstructive sleep apnea, which is significantly underdiagnosed in older adults. A sleep study can now be done at home with equipment your doctor prescribes, making it more accessible than the overnight lab studies of the past. If moderate-to-severe OSA is confirmed, that opens the Part D coverage pathway for Zepbound — a route that currently has no expiration date, unlike the GLP-1 Bridge. For Medicare patients with both obesity and undiagnosed sleep apnea, getting tested could meaningfully change their coverage options for Zepbound starting now, rather than waiting for Bridge program processing.

🩸 My A1C is 6.2% — I have pre-diabetes but not diabetes

Pre-diabetes (A1C 5.7–6.4%) qualifies you for the GLP-1 Bridge if your BMI is 27 or higher under Tier 3. Document your pre-diabetes diagnosis in your medical record per American Diabetes Association guidelines — your doctor may need to confirm this designation in your chart. Have your prescriber submit prior authorization to the CMS Bridge processor. At your BMI and diagnosis, you qualify. This is exactly the clinical scenario the Bridge was designed for — people at elevated metabolic risk who are not yet diabetic and would benefit from GLP-1 treatment to prevent progression.

💊 I have type 2 diabetes — how do I get tirzepatide through Medicare?

Ask your doctor to prescribe Mounjaro (not Zepbound) for your diabetes management. Mounjaro is the FDA-approved brand for type 2 diabetes and the name your Part D plan will look for when processing the claim. Your plan’s formulary and prior authorization requirements apply — confirm Mounjaro’s tier on your plan’s drug list at medicare.gov or by calling the plan directly. If it’s not on your formulary, request a formulary exception with your doctor’s support. If your plan covers it, the $2,100 annual out-of-pocket cap on Part D drugs limits your maximum yearly cost.

❌ My Part D plan denied Zepbound for weight loss — what now?

First: confirm that the claim was actually routed to the GLP-1 Bridge processor and not your Part D plan — because standard Part D legally cannot cover weight-loss drugs, a denial from Part D for that reason is correct but doesn’t mean you can’t get it through the Bridge. If the denial came from the Bridge processor, read the denial letter for the specific reason, ask your doctor to provide additional documentation of your qualifying BMI and conditions, and file a redetermination within 60 days. Call 1-800-Medicare and contact your local SHIP counselor for free help with the appeal.

💰 I can’t afford Zepbound and don’t qualify for any coverage pathway

LillyDirect is Eli Lilly’s direct-to-patient pharmacy that sells tirzepatide vials at $299–$449 per month, bypassing insurance entirely. This is a cash-pay option that works outside your Medicare coverage — it doesn’t count toward your Part D out-of-pocket maximum, but it’s dramatically cheaper than retail pharmacy pricing. Separately, check whether you qualify for Extra Help / Low Income Subsidy at ssa.gov — if approved, your copays on covered drugs drop significantly and this benefit is specifically for people who need help with prescription costs. Your state’s SHIP office can help you apply for Extra Help at no charge.

☎️ Where to Get Help

Navigating Medicare drug coverage — especially for a new and evolving program like the GLP-1 Bridge — can feel overwhelming. These are the right people to contact for each type of question.

☎️ 1-800-Medicare — 24/7 🌐 medicare.gov 🔗 Free SHIP Counseling 💰 Extra Help / LIS — SSA 🏛️ CMS GLP-1 Bridge Info

📞 Who to Contact for Each Question

Does my Part D plan cover Zepbound for OSA? — Call the member services number on your insurance card, or look up your plan’s formulary at medicare.gov/drug-coverage-part-d
Do I qualify for the GLP-1 Bridge? — Talk to your prescribing doctor, who will submit the prior authorization; you don’t enroll separately
My claim was denied — what do I do? — Call 1-800-Medicare and contact your local SHIP counselor at shiphelp.org; both are free
Do I qualify for Extra Help? — Apply through Social Security at ssa.gov or call 1-800-772-1213
How much will Zepbound cost with my specific plan? — Call your plan directly with the drug name and your plan member ID; also check medicare.gov’s plan finder drug cost tool

This guide provides general educational information about Medicare coverage policies for Zepbound (tirzepatide) based on publicly available CMS policy, FDA approvals, and coverage rules as of mid-2026. It is not medical advice and does not substitute for guidance from your doctor, pharmacist, or a licensed Medicare counselor. Coverage rules, formulary placement, prior authorization requirements, program eligibility criteria, and copayment amounts change frequently and vary by plan. Always verify current coverage with your specific Medicare Part D plan and with CMS. The Medicare GLP-1 Bridge is a time-limited demonstration program; its continuation beyond December 31, 2027, has not been confirmed. References to the BALANCE Model reflect its scheduled but unimplemented status as of the time of writing. Consult your healthcare provider before starting, stopping, or changing any medication.

🛡️ Insurance

Recommended Reads

Leave a Reply Cancel reply